NasdaqCM - Delayed Quote USD
INmune Bio, Inc. (INMB)
7.68
-0.09
(-1.16%)
At close: May 20 at 4:00:00 PM EDT
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
50
14
155
374
181
Operating Expense
41,573
42,649
29,896
26,325
29,334
Operating Income
-41,523
-42,635
-29,741
-25,951
-29,153
Other Income Expense
727
553
-267
-1,348
-1,187
Pretax Income
-40,796
-42,082
-30,008
-27,299
-30,340
Net Income Common Stockholders
-40,796
-42,082
-30,008
-27,299
-30,340
Diluted NI Available to Com Stockholders
-40,796
-42,082
-30,008
-27,299
-30,340
Basic EPS
-1.93
--
-1.67
-1.52
-1.88
Diluted EPS
-1.93
--
-1.67
-1.52
-1.88
Basic Average Shares
21,061.73
--
17,980.79
17,927.33
16,130.54
Diluted Average Shares
21,061.73
--
17,980.79
17,927.33
16,130.54
Total Operating Income as Reported
-41,523
-42,635
-29,741
-25,951
-29,153
Total Expenses
41,573
42,649
29,896
26,325
29,334
Net Income from Continuing & Discontinued Operation
-40,796
-42,082
-30,008
-27,299
-30,340
Normalized Income
-40,796
-42,082
-30,008
-27,299
-30,340
EBIT
-41,523
-42,635
-29,741
-25,951
-29,153
EBITDA
-41,523
-42,635
-29,741
-25,951
-29,153
Net Income from Continuing Operation Net Minority Interest
-40,796
-42,082
-30,008
-27,299
-30,340
Normalized EBITDA
-41,523
-42,635
-29,741
-25,951
-29,153
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0
12/31/2021 - 2/4/2019
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
COYA Coya Therapeutics, Inc.
5.86
-1.84%
BDTX Black Diamond Therapeutics, Inc.
2.1700
+2.84%
ANVS Annovis Bio, Inc.
2.1400
+0.94%
GANX Gain Therapeutics, Inc.
1.9100
-2.55%
IMUX Immunic, Inc.
0.9736
+1.34%
CRDF Cardiff Oncology, Inc.
3.0700
+5.50%
PRTA Prothena Corporation plc
7.29
-1.49%
CRVS Corvus Pharmaceuticals, Inc.
3.6800
+1.66%
AVXL Anavex Life Sciences Corp.
7.53
-10.78%
ANIX Anixa Biosciences, Inc.
2.6100
-3.33%